

CORRECTION

Correction: 2-Day versus C-reactive protein guided antibiotherapy with levofloxacin in acute COPD exacerbation: A randomized controlled trial


The *PLOS ONE* Staff

Notice of republication

An incorrect version of Fig 1 was published in error. The publisher apologizes for the error. This article was republished on June 1, 2021, to correct for this error. Please download this article again to view the correct version.

Reference

1. Mohamed Amine M, Selma M, Adel S, Khaoula Bha, Mohamed Hassene K, Imen T, et al. (2021) 2-Day versus C-reactive protein guided antibiotherapy with levofloxacin in acute COPD exacerbation: A randomized controlled trial. *PLoS ONE* 16(5): e0251716. <https://doi.org/10.1371/journal.pone.0251716> PMID: [34015041](https://pubmed.ncbi.nlm.nih.gov/34015041/)



OPEN ACCESS

Citation: The *PLOS ONE* Staff (2021) Correction: 2-Day versus C-reactive protein guided antibiotherapy with levofloxacin in acute COPD exacerbation: A randomized controlled trial. *PLoS ONE* 16(6): e0253252. <https://doi.org/10.1371/journal.pone.0253252>

Published: June 9, 2021

Copyright: © 2021 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.